Skip to evidence report

T.CD4_transitional.APC_interacting: Studies

How association tiers are defined — cell–trait and gene–trait

SCREATE tier definitions supplied by the atlas curator. This methods note explains the prepared classifications; it does not recompute or change any report scores or tiers.

Cell–trait tiers

Cell–trait links
Identify cell types whose regulatory activity is associated with a trait’s genetic signal.
Required for Specific or Relevant
The ICE-CREAM score derived from the mean metacell Z score must be ≥ 5.39, with BOTH nominal and adjusted ICE-CREAM P values ≤ 0.05.
Specific (Tier 1)
Also meets all cell-set enrichment analysis (CSEA) criteria in at least one tested comparison: nominal P ≤ 0.05 AND adjusted P ≤ 0.05 AND normalized enrichment score (NES) ≥ 1, all in that comparison. This indicates that trait-associated activity is concentrated in this cell type relative to the tested background.
Relevant (Tier 2)
Meets the ICE-CREAM requirements but not the additional CSEA criteria. The cell type may share trait-associated activity with other cell types.
Interpretation and report values
CSEA is cell-set enrichment analysis, analogous to gene-set enrichment analysis but using sets of cells along a ranked list of ICE-CREAM scores. The eligibility score derived from the mean metacell Z score is not the displayed mean IC score. Do not infer a tier from the displayed mean, its descriptive Significance column, or a single CSEA summary value. Reports preserve prepared tiers; Other means an available association outside Specific/Relevant, and unavailable is not zero or proof of biological irrelevance.
Meta traits and individual traits
Use the prepared tier for the exact meta trait or individual trait. A meta trait’s Best child CSEA FDR is the lowest available child FDR, not a combined or meta-trait significance test. Its displayed mean child NES is descriptive, not a new CSEA test. These summaries must not be used to reconstruct or override the meta-trait tier.

Gene–trait priorities (variant–tCRE–gene evidence)

Variant–tCRE–gene links
Candidate variants connect to genes through overlapping promoters or distal transcribed cis-regulatory elements (tCREs) linked to gene promoters by the Activity-by-Contact (ABC) model.
Required genetic support
The variant belongs to a purity-passing SuSiE credible set OR qualifies for Borzoi rescue. Borzoi rescue requires BOTH a variant-causality score ≥ 0.3 AND linkage disequilibrium with the lead variant of r² ≥ 0.2.
Required cellular support
The overlapping promoter has positive tCRE activity OR the distal element has a passing cell-specific ABC link to the gene, in a Specific or Relevant cell subtype (L1S) or fine-grained state (L2). BOTH genetic and cellular support are required for High or Medium priority.
High priority
Among records meeting both minimum requirements, High requires a genetic score ≥ 0.5 AND a Layer 1 correlation > 0.3 between tCRE activity and the trait’s cellular profile across cell subtypes.
Medium priority
Meets both minimum requirements but not one or both additional High thresholds. The genetic score is the higher of the SuSiE posterior inclusion probability (PIP) and the Borzoi variant-causality score.
Same-record evidence and aggregation
Each priority requires genetic and cellular evidence supporting the SAME variant–tCRE–gene record. Do not combine thresholds or evidence from different records to create a qualifying link. A gene receives the highest priority observed among its supporting records. A tCRE summary uses supporting records for that exact tCRE, not every trait of its linked genes. Separately displayed aggregate scores do not relax the same-record rule.
Limits of interpretation
A priority is candidate-association evidence, not proof of a causal variant, causal gene, causal cell type or treatment efficacy. Missing evidence is unavailable, not zero. MAGMA −log10(P), displayed credibility scores, cellular-context scores and G/C tier codes must not be substituted for these eligibility tests; use the provided records and their documented fields.

State · 733 full-atlas cells · all tissues.

Marker genes and cell annotation · Open this population in Cell Browser →

ICE-CREAM (IC) is −log10(P) from a permutation test. An IC score of 3 corresponds to an unadjusted P value of 0.001; 5.5 is the multiple-testing-corrected significance threshold across all metacells. The Significance categories are Significant for IC > 5.5, Nominal for 3 ≤ IC ≤ 5.5, and Nonsignificant for IC < 3. These reports display mean IC scores across full-atlas populations, not the UMAP sample. The categories apply to the displayed scores: a cell-group mean or an average across individual traits is descriptive and is not itself a newly tested P value or a new multiple-testing correction. All scores are retained. Enrichment is not proof of causality or treatment efficacy.

Rows 1–1,000 of 12,313; ranked by score descending. Equal values use name/identifier order.

Studies ranked for T.CD4_transitional.APC_interacting
#Trait / studyIndividual trait IDMean IC score
1Other/unspecified rheumatoid arthritisFING0000112638.85
2Allergic contact dermatitisFING0000006836.28
3Papulosquamous disordersFING0000114433.49
4Hypothyroidism NOS (PheCode 244.4)GCST9047565332.99
5CD5/TNFRSF9 ratioGCST9031386232.89
6Hypothyroidism (PheCode 244)GCST9047564732.81
7Thyroid problemsGCST9047527632.46
8Psoriasis vulgaris (PheCode 696.41)GCST9047619031.27
9Psoriatic arthritisGCST9024395631.26
10Psoriasis (PheCode 696.4)GCST9047618730.43
11Non-cancer illness code, self-reported - hypothyroidism/myxoedema | Medical conditionsUKBB0000051830.43
12Treatment/medication code - levothyroxine sodium | MedicationsUKBB0000084929.32
13Hypothyroidism, strict autoimmuneFING0000065628.91
14Reimbursement for rheumatic diseasesFING0000124728.90
15Psoriasis and related disorder (PheCode 696)GCST9047618628.78
16Lymphocyte countGCST9001874228.67
17Disorders of the thyroid glandFING0000046328.59
18FCRL6 levelsGCST9046920928.35
19Autoimmune diseases excluding thyroid diseasesFING0000013227.93
20Second line medication for Crohn's diseaseFING0000128427.89
21Psoriasis vulgarisFING0000122427.53
22Lymphocyte countGCST9002598427.48
23Rheumatoid arthritisFING0000126727.33
24Non-cancer illness code, self-reported - eczema/dermatitis | Medical conditionsUKBB0000050926.73
25Type 1 diabetesGCST9000052926.51
26IL2RB levelsGCST9046958626.45
27Seropositive rheumatoid arthritis, strict definitionFING0000129726.43
28CD5 levelsGCST9046864126.42
29Treatment or medication use - levothyroxine sodium (UKB data field 20003_1141191044)GCST9004253526.12
30HypothyroidismGCST9020416726.00
31Autoimmune diseasesFING0000013125.61
32HypothyroidismGCST9046813825.57
33Lymphocyte countGCST9000231725.47
34Takes medication for Thyroid problems?GCST9047527725.35
35Hypothyroidism | endocrine/metabolicUKBB0000033525.29
36Nasal polyps (PheCode 471)GCST9047601925.15
37Other (seronegative) rheumatoid arthritis, wideFING0000091725.13
38lymphocyte (absolute count, mean, inv-norm transformed)GCST9047542624.74
39Graves disease, strict definitionFING0000059224.71
40Other hypothyroidism | Disorders of thyroid glandUKBB0000061124.52
41Hypothyroidism NOS | endocrine/metabolicUKBB0000033624.39
42Allergic disease (asthma, hay fever or eczema)GCST00503824.33
43Blood clot, DVT, bronchitis, emphysema, asthma, rhinitis, eczema, allergy diagnosed by doctor - Hayfever, allergic rhinitis or eczema | Medical conditionsUKBB0000010024.28
44Multiple sclerosisGCST9047583324.17
45Asthma (childhood onset)GCST00780024.15
46PAG1 levelsGCST9047014724.07
47TNFRSF8 levelsGCST9047091524.07
48Nasal polypFING0000085824.00
49CXCL9 levelsGCST9046893523.98
50SKAP1 levelsGCST9047064523.55
51Dermatitis and eczemaFING0000040223.52
52lymphocyte (absolute count, minimum, inv-norm transformed)GCST9047542923.23
53ITGAL levelsGCST9046963723.06
54CD48/CRTAM ratioGCST9031383922.98
55ThyrotoxicosisFING0000136022.94
56Blood clot, DVT, bronchitis, emphysema, asthma, rhinitis, eczema, allergy diagnosed by doctor - None of the above | Medical conditionsUKBB0000010122.89
57Type1 diabetes, definitions combined, early onsetFING0000138422.87
58CRTAM/FCRL6 ratioGCST9031427422.82
59First line medication for Crohn's diseaseFING0000054422.79
60PAFAH1B3 levelsGCST9047014522.77
61HypothyroidismGCST9031932022.75
62Malignant neoplasm of bronchus and lung, excluding all cancers (controls excluding all cancers)FING0000075622.74
63lymphocyte (absolute count, maximum, inv-norm transformed)GCST9047542322.65
64KLRB1 levelsGCST9046970922.36
65PDCD1 levelsGCST9047018122.25
66Lymphocyte count | Blood countUKBB0000041122.05
67CD160/KLRB1 ratioGCST9031373122.03
68Asthma | respiratoryUKBB0000005422.03
69Asthma | Chronic lower respiratory diseasesUKBB0000005321.90
70Graves' diseaseGCST9001862721.85
71Atopic dermatitisFING0000012521.82
72Ceramide (d18:2/22:0) levelsGCST9002468221.81
73Eosinophill percentage (UKB data field 30210)GCST9046806921.77
74GZMH levelsGCST9046942521.75
75Preterm labour and deliveryFING0000120921.69
76Asthma-related infectionsFING0000011821.68
77HyperthyroidismGCST9046813621.49
78HyperthyroidismGCST9031931921.48
79Prescriptions - levothyroxine | thyroid hormoneUKBB0000068721.37
80Prescriptions - thyroid hormone | hormoneUKBB0000070521.37
81CXCL16 levelsGCST9046892821.21
82Noninfective enteritis and colitisFING0000088121.14
83Eosinophill percentage | Blood countUKBB0000020721.08
84CRTAM/VCAM1 ratioGCST9031428121.04
85GZMB levelsGCST9046942420.89
86Eosinophill count | Blood countUKBB0000020620.84
87Eosinophil countGCST9002598720.81
88PolyarthropathiesFING0000118020.63
89Lymphocyte count (UKB data field 30120)GCST9046808220.61
90Crohn disease (strict definition, require KELA, min 2 HDR)FING0000036620.60
91Eosinophil percentage of granulocytesGCST00461720.57
92Eosinophil percentage of white cellsGCST00460020.52
93Atopic dermatitisGCST9002716120.51
94Type 1 diabetesGCST9001379120.44
95KLRF1 levelsGCST9046971220.41
96IL15 levelsGCST9046955620.17
97Lymphocyte countGCST00462720.03
98EczemaGCST9046812620.00
99Neutrophil percentage of granulocytesGCST00462320.00
100Coeliac diseaseGCST9046812019.94
101Asthma-related acute respiratory infectionsFING0000011719.78
102Lymphocyte countGCST9000238819.75
103IL15/IL18BP ratioGCST9031514819.74
104Myasthenia gravisGCST9043215619.67
105Mosaic chromosomal alteration of the X chromosomeGCST9016528719.67
106Atopic/contact dermatitis due to other or unspecified (PheCode 939)GCST9047628919.65
107Eosinophil percentage of white cellsGCST9000238219.62
108Age hay fever, rhinitis or eczema diagnosed | Medical conditionsUKBB0000001519.43
109Chronic lower respiratory diseasesFING0000029019.38
110EndometriosisGCST9001861919.34
111Rash and other nonspecific skin eruption (PheCode 687.1)GCST9047616719.29
112Thyrotoxicosis with diffuse goitreFING0000136119.25
113Lymphocyte countGCST9000231619.25
114Type 1 diabetesGCST9001402319.23
115Suggestive for eosinophilic asthmaFING0000134419.17
116Autoimmune hyperthyroidismFING0000013419.11
117MS-disease / Multiple SclerosisFING0000083919.09
118Asthma (adult onset)GCST00779919.07
119Seropositive rheumatoid arthritis, wideFING0000129819.04
120Allergy/adverse effect of penicillin | injuries & poisoningsUKBB0000002818.99
121HLAE/IL15 ratioGCST9031506118.88
122CD6 levelsGCST9046864418.87
123Primary biliary cholangitisGCST9006144018.84
124Chronic sinusitisFING0000029818.83
125PDCD1/TNFRSF8 ratioGCST9031561018.81
126Eosinophil countGCST00460618.75
127NCR1 levelsGCST9047000918.74
128MAVS/TBL1X ratioGCST9031539918.68
129Eosinophill count (UKB data field 30150)GCST9046806818.68
130CD160/CXCL16 ratioGCST9031372818.65
131Asthma/COPD (KELA code 203)FING0000012118.63
132Handedness (chirality/laterality) - Left-handed | Early life factorsUKBB0000030218.60
133eosinophil (fraction, minimum, inv-norm transformed)GCST9047530318.58
134Lymphoid neoplasmsGCST9062474318.48
135AsthmaGCST9046811218.34
136AsthmaGCST01004218.32
137PsoriasisFING0000122218.30
138CD244/CRTAM ratioGCST9031376318.17
139Respiratory disease (confirmatory factor analysis Factor 11)GCST9030934518.15
140Asthma (only as main-diagnosis) (more control exclusions)FING0000011418.12
141SIT1 levelsGCST9047064418.05
142HSIL lesion of the cervix uteriFING0000062417.95
143Ceramide (d18:2/24:1) levelsGCST9002468417.93
144Eosinophil countGCST9000238117.71
145Eosinophil countGCST9001873317.69
146Eosinophil countGCST9000229817.68
147Inflammatory bowel disease, strict (require KELA)FING0000067517.53
148Sum eosinophil basophil countsGCST00462417.51
149GZMA/GZMH ratioGCST9031500817.50
150Blood clot, DVT, bronchitis, emphysema, asthma, rhinitis, eczema, allergy diagnosed by doctor - Asthma | Medical conditionsUKBB0000009817.46
151Graves' disease (PheCode 242.1)GCST9047564417.45
152Hypothyroidism, drug reimbursementFING0000065517.42
153Seronegative rheumatoid arthritisFING0000129617.34
154ChalazionFING0000026717.31
155eosinophil (fraction, mean, inv-norm transformed)GCST9047530017.27
156HSIL lesion of the cervix uteri, vagina or vulvaFING0000062517.27
157PsoriasisGCST9046814717.26
158DermatitisFING0000040117.25
159Rheumatoid arthritisGCST9001869017.17
160CRTAM/LY9 ratioGCST9031427817.15
161HippSubfield lh volume GC-ML-DG-headGCST9000267917.06
162lymphocyte (fraction, minimum, inv-norm transformed)GCST9047543817.04
163Asthma (more control exclusions)FING0000011316.92
164Lymphoid neoplasms (somatic mutation group 2 phenocluster)GCST9062475016.77
165Lymphoid neoplasms (drug group 1 phenocluster)GCST9062474016.68
166Lymphoid neoplasms (B-cell phenocluster)GCST9062473616.62
167CD160 levelsGCST9046859916.61
168CD244/FCRL6 ratioGCST9031376516.56
169Basal cell carcinoma (MTAG)GCST9013741116.55
170eosinophil (fraction, maximum, inv-norm transformed)GCST9047529716.50
171TXNL1 levelsGCST9047099316.48
172Blood cell traits latent factor 23 (white cell)GCST9055926516.30
173CD8 on Effector Memory CD8+ T cellGCST9000205616.29
174Non-cancer illness code, self-reported - hayfever/allergic rhinitis | Medical conditionsUKBB0000051316.26
175Erythematosquamous dermatosis (PheCode 690)GCST9047617016.23
176Rheumatoid arthritisGCST9013222316.19
177MZB1 levelsGCST9046998716.16
178Personal history of allergy to drugs, medicaments and biologocal substances | Persons with potential health hazards related to family and personal history and certain conditions influencing health statusUKBB0000064116.16
179Seborrheic dermatitis (PheCode 690.1)GCST9047617116.13
180Type 1 diabetes, definitions combinedFING0000138016.04
181Blood cell traits latent factor 20 (red cell)GCST9055926216.04
182GNLY levelsGCST9046937216.03
183GZMA/GZMB ratioGCST9031500716.01
184Non-cancer illness code, self-reported - asthma | Medical conditionsUKBB0000050615.99
185Vanillactate levelsGCST9019997815.95
186Childhood asthma (age<16) (more control exclusions)FING0000027015.89
187Right-hemisphere dorsal attention network to amygdala white-matter structural connectivityGCST9030281115.86
188OSMR levelsGCST9047013215.86
189IL1RL1 levelsGCST9046957415.70
190Lichen sclerosus et atrophicusFING0000072315.63
191GZMB/IL15 ratioGCST9031501515.55
192Avoided activities or situations because of previous stressful experience in past month | Traumatic eventsUKBB0000008315.48
193eosinophil (absolute count, minimum, inv-norm transformed)GCST9047529415.42
194Myasthenia gravisGCST9009306115.36
195Mean corpuscular hemoglobin concentrationGCST9001874515.33
196Lichen simplex chronicus and prurigoFING0000072515.26
197Monoclonal gammopathy of undetermined significanceGCST9062474515.21
198Late-onset myasthenia gravisGCST9009346615.18
199CD8A levelsGCST9046865515.08
200Eosinophil countGCST9000229915.07
201Rheumatoid arthritisGCST9013222414.99
202DTI TBSS L3 Cingulum hippocampus RGCST9038456014.91
203IL2RA levelsGCST9046958514.91
204Regional enteritis (PheCode 555.1)GCST9047606614.89
205SarcoidosisGCST9050348314.88
206CLC levelsGCST9046876214.82
207FCRL5/LY96 ratioGCST9031480314.77
208AsthmaGCST9047602414.76
209Mean reticulocyte volumeGCST9002597514.75
210AsthmaGCST9001432514.68
211SarcoidosisFING0000127514.59
212IL5RA/TNFRSF13B ratioGCST9031516414.59
213HEXIM1/TBL1X ratioGCST9031505314.51
214Sicca syndrome [Sjögren]FING0000130414.50
215Thyroid peroxidase antibody levels in pregnancyGCST9043520114.44
216eosinophil (absolute count, mean, inv-norm transformed)GCST9047529114.39
217Paraproteinemia (PheCode 270.32)GCST9047571014.37
218CD79B/TNFRSF4 ratioGCST9031390314.32
219CD7 levelsGCST9046864914.20
220Other diseases of upper respiratory tractFING0000101214.19
221Mouth/teeth dental problems - None of the above | MouthUKBB0000048914.15
222Poisoning by antibiotics | injuries & poisoningsUKBB0000065314.14
223eosinophil (absolute count, maximum, inv-norm transformed)GCST9047528814.14
224Infective dermatitisFING0000067314.12
225ATOX1/SNAP29 ratioGCST9031337414.01
226CCL19 levelsGCST9046857114.01
227CD27/NBL1 ratioGCST9031377413.99
228Mean corpuscular hemoglobin concentrationGCST9000232913.93
229AsthmaGCST9047525913.92
230Early-onset myasthenia gravisGCST9009346513.90
231lymphocyte (fraction, mean, inv-norm transformed)GCST9047543513.89
232CC2D1A/STAMBP ratioGCST9031366413.86
233TNFRSF17 levelsGCST9047090813.73
234Dermatomycosis (PheCode 110.2)GCST9047556513.73
235Disorders of orbitFING0000044913.69
236Lymphocyte percentage (UKB data field 30180)GCST9046808313.67
237Thyroid peroxidase antibody positivity in pregnancyGCST9043520213.66
238Lymphocyte percentage | Blood countUKBB0000041213.65
239IridocyclitisFING0000069613.55
240Right-hemisphere somatomotor network to amygdala white-matter structural connectivityGCST9030279913.53
241GRAP2/SRC ratioGCST9031498913.53
242Left-hemisphere control network to amygdala white-matter structural connectivityGCST9030275713.49
243T1 FreeSurfer aseg MaskVol-to-eTIVGCST9038419213.49
244PsoriasisGCST9001901613.48
245PRG3 levelsGCST9047032313.36
246Medication use (drugs affecting bone structure and mineralization)GCST9001877313.34
247AsthmaGCST00686213.34
248Crohn's disease NASFING0000036713.29
249Thyroid peroxidase antibody positivity with euthyroid in pregnancyGCST9043520313.29
250Primary biliary cholangitisGCST00312913.24
251Ulcerative colitisGCST9044679513.17
252SH2B3/TBL1X ratioGCST9031584113.16
253Lymphocyte percentage of white cellsGCST9000238913.14
254Dissociative [conversion] disordersFING0000046813.14
255Wheeze or whistling in the chest in last year | BreathingUKBB0000091213.13
256Doctor diagnosed hayfever or allergic rhinitis | Medical informationUKBB0000019213.12
257Obesity related asthmaFING0000089713.07
258CXCL16/NOTCH1 ratioGCST9031433913.07
259Pulmonary fibrosisGCST9001868813.04
260Blood cell traits latent factor 9 (white cell)GCST9055925112.97
261Inflammatory bowel diseaseGCST9043218212.95
262Allergic asthma (mode)FING0000006612.89
263Rheumatoid arthritis (PheCode 714.1)GCST9047623012.89
264IL15/NCR1 ratioGCST9031515012.83
265TPSAB1 levelsGCST9047095112.81
266Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive)GCST9013222712.71
267CRTAM levelsGCST9046887112.69
268Acute upper respiratory infectionsFING0000003412.66
269Vitamin B12 deficiency anaemiaFING0000144112.62
270CD5/IL16 ratioGCST9031386112.56
271LTA levelsGCST9046981312.54
272Lichen ruber planus, wide definition including periferal and oral lichen planusFING0000072212.46
273ATP5IF1/METAP1D ratioGCST9031339112.46
274ICD10 O60: Preterm labor and deliveryGCST9045424212.43
275HayfeverGCST9046813112.40
276Cancer of urinary organs (incl. kidney and bladder) (PheCode 189)GCST9047559312.37
277Left-hemisphere dorsal attention network to amygdala white-matter structural connectivityGCST9030270612.32
278Neutrophils and lymphocytes in blood (confirmatory factor analysis Factor 35)GCST9030936912.24
279mean corpuscular volume (MCV, minimum, inv-norm transformed)GCST9047547412.22
280PALM2 levelsGCST9047015212.17
281Other noninfective gastroenteritis and colitisFING0000107712.14
282Nasal polyps | respiratoryUKBB0000049412.09
283EDAR/LAT2 ratioGCST9031458212.04
284Skin cancerGCST9047557512.02
285CD27/TGFBR2 ratioGCST9031377611.98
286CDSN/WFDC12 ratioGCST9031399911.94
287Rheumatoid arthritisGCST00067911.89
288Smoking status (weighted GWA)GCST9026730311.87
289HippSubfield lh volume CA4-headGCST9000268211.83
290Basal cell carcinoma (PheCode 172.21)GCST9047558211.81
291Percentage of monosialylation of core-fucosylated monogalactosylated structures without bisecting GlcNAc (GP41)GCST9066848511.76
292Cervicalgia (PheCode 761)GCST9047626711.69
293IL22 levelsGCST9046958211.66
294PPP1R2/TBL1X ratioGCST9031572011.61
295IFNG levelsGCST9046951511.60
296CD48/FCRL6 ratioGCST9031384011.58
297mean corpuscular volume (MCV, maximum, inv-norm transformed)GCST9047546611.56
298mean corpuscular volume (MCV, mean, inv-norm transformed)GCST9047547011.54
299CD160/NCR1 ratioGCST9031373211.54
300lymphocyte (fraction, maximum, inv-norm transformed)GCST9047543211.51
301Crohn's disease of small intestineFING0000036911.49
302Asthma and allergyFING0000011511.40
303Inflammatory bowel disease and other gasteroenteritis and colitis (PheCode 555)GCST9047606511.37
304Pain type(s) experienced in last month - Pain all over the body | PainUKBB0000063211.33
305Interpolated Year when non-cancer illness first diagnosed | Medical conditionsUKBB0000037111.30
306Operation code - tonsillectomy +/- adenoids | OperationsUKBB0000056711.28
307Blood cell traits latent factor 12 (red cell)GCST9055925411.26
308Nasal polyp | Other diseases of upper respiratory tractUKBB0000049311.26
309Systemic lupus erythematosusGCST9001186611.25
310Coeliac diseaseFING0000031211.24
311DNAJC21 levelsGCST9046901611.23
312Taking other prescription medications | MedicationUKBB0000081311.19
313Seborrhoeic dermatitisFING0000128211.18
314Treatment or medication use - insulin product (UKB data field 20003_1140883066)GCST9004222611.14
315NECTIN2/NPDC1 ratioGCST9031552811.11
316Chronic lymphocytic leukemiaGCST9062473811.10
317Cold medicine-related Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) with severe ocular complicationsGCST9009311311.10
318DTI TBSS L2 External capsule LGCST9038450911.04
319T1 FreeSurfer aseg Right-choroid-plexusGCST9038417011.04
320GZMH/KLRD1 ratioGCST9031501611.01
321Bread type: Wholemeal/wholegrain vs white and brown (UKB data field 1448)GCST9013296810.96
322Disorders of sclera, cornea, iris and ciliary bodyFING0000045810.95
323DAPP1/ITGB1BP2 ratioGCST9031438810.92
324CXCL10 levelsGCST9046892310.90
325X-21285 levelsGCST9020057610.89
326PRG2 levelsGCST9047032210.83
327Lymphocyte percentage of white cellsGCST00463210.79
328Mean corpuscular hemoglobin concentrationGCST9000239110.78
329Pollen allergyFING0000117610.78
330IFI30 levelsGCST9046950910.72
331DTI autoptx L2 slf l tractGCST9038518710.68
332DTI TBSS MD Superior corona radiata LGCST9038459710.66
333ICD10 N84: Polyp of female genital tractGCST9045421610.64
334CRTAM/TNFRSF9 ratioGCST9031428010.62
335Volume of right cortical nucleusGCST9047503310.61
336Lymphoid neoplasms (P-cell phenocluster)GCST9062473710.56
337DTI TBSS L1 Cingulum cingulate gyrus LGCST9038446310.56
338mean corpuscular hemoglobin (MCH, maximum, inv-norm transformed)GCST9047544210.48
339Average total household income before tax | HouseholdUKBB0000008110.47
340Blood cell traits latent factor 17 (white cell)GCST9055925910.46
341ICD10 N97.8: Female infertility of other originGCST9045422510.43
342Treatment/medication code - ventolin 100micrograms inhaler | MedicationsUKBB0000086010.42
343Rheumatoid arthritis and other inflammatory (PheCode 714)GCST9047622810.41
344Mean reticulocyte volume | Blood countUKBB0000045110.37
345S100A11/S100A12 ratioGCST9031579810.36
346FUT8/TNFSF14 ratioGCST9031489510.33
347Diseases of hair and hair follicles (PheCode 704)GCST9047620910.31
348Ulcerative colitisGCST00413310.28
349Rheumatoid arthritis | musculoskeletalUKBB0000075710.27
350CD74/NPDC1 ratioGCST9031389510.26
351Eye autorefraction and astigmatism (confirmatory factor analysis Factor 24)GCST9030935810.23
352CRACR2A/LBR ratioGCST9031422810.22
353Chronic obstructive pulmonary disease in current smokersGCST9001659310.19
354Symptoms concerning nutrition, metabolism, and development (PheCode 1002)GCST9047555610.18
355BLNK levelsGCST9046844810.18
356Mouth/teeth dental problems - Mouth ulcers | MouthUKBB0000048810.17
357CPXM1/HBEGF ratioGCST9031421910.17
358Prescriptions - tramadol | opioid analgesic,selective serotonin re-uptake inhibitor,norepinephrine re-uptake inhibitorUKBB0000070610.16
359Prescriptions - opioid analgesic|selective serotonin re-uptake inhibitor|norepinephrine re-uptake inhibitorUKBB0000069410.16
360Mean corpuscular hemoglobin concentrationGCST9000232810.16
361Systemic connective tissue disordersFING0000135010.15
362CRTAM/ICAM3 ratioGCST9031427610.10
363GOPC/IRAK4 ratioGCST9031495410.08
364mean corpuscular hemoglobin (MCH, mean, inv-norm transformed)GCST9047544610.08
365FOXO3/SH2B3 ratioGCST9031488110.03
366Melanomas of skin, dx or hx (PheCode 172.1)GCST9047557710.02
367mean corpuscular hemoglobin (MCH, minimum, inv-norm transformed)GCST9047545010.02
368Snoring | SleepUKBB0000078410.00
369LY6D/WFDC12 ratioGCST903153469.99
370Basal cell carcinomaGCST900134109.96
371Other specified disorders of external earFING000011049.94
372aparc-a2009s rh thickness G-temporal-middleGCST900037149.94
373MZB1/TNFRSF13B ratioGCST903155099.93
374KLRK1 levelsGCST904697139.92
375Celiac disease (PheCode 557.1)GCST900441589.92
376CRTAM/GZMA ratioGCST903142759.90
377Other non-epithelial cancer of skin (PheCode 172.2)GCST904755809.90
378Type 1 diabetesGCST904320669.86
379IGLC2 levelsGCST904695369.79
380Skin cancerGCST904751899.78
381SH2D1A levelsGCST904706179.74
382ENO2/RWDD1 ratioGCST903146679.73
383IDP dMRI TBSS L1 Posterior limb of internal capsule RGCST900040939.68
384B2M levelsGCST904684099.62
385CA1/HMBS ratioGCST903135739.59
386TIGIT levelsGCST904708659.57
387Multiple myeloma or monoclonal gammopathy of undetermined significanceGCST906247469.51
388Lymphoid leukemia, chronic (PheCode 204.12)GCST904756139.49
389SRP14 levelsGCST904707429.49
390ELOA/POLR2F ratioGCST903146439.49
391Mean sphered cell volume | Blood countUKBB000004529.45
392MPHOSPH8/USP8 ratioGCST903154799.45
393SH3GLB2 levelsGCST904706219.42
394STX6 levelsGCST904707749.39
395MAPRE3 levelsGCST904698599.39
396Erythematous conditions (PheCode 695)GCST904761779.37
397Follicular lymphoma, hilmo (controls excluding all cancers)FING000005489.34
398EZR levelsGCST904691629.32
399RBFOX3 levelsGCST904704329.30
400CAPG levelsGCST904685379.23
401TFRC levelsGCST904708409.22
402Rosacea (PheCode 695.3)GCST904761789.21
403CD27/DLL1 ratioGCST903137719.20
404HippSubfield lh volume Hippocampal-tailGCST900026689.19
405ATP5IF1/LYN ratioGCST903133899.19
406Handedness (chirality/laterality) - Right-handed | Early life factorsUKBB000003039.15
407Asthma, unspecified (mode)FING000001209.12
408aseg lh volume HippocampusGCST900026249.11
409rfMRI connectivity (ICA100 edge 605)GCST900054589.10
410Chromatiales abundance in stoolGCST900323189.08
411MelanomaGCST900118099.07
412MAP2K6/TBL1X ratioGCST903153789.04
413CDSN/LY6D ratioGCST903139979.02
414Wheeze or whistling in the chest in last year (UKB data field 2316)GCST900436148.99
415Malignant neoplasm of skin, excluding all cancers (controls excluding all cancers)FING000007728.96
416Mean sphered cell volume (UKB data field 30270)GCST904680898.93
417CD27 levelsGCST904686158.93
418BMP7 levelsGCST900881578.91
419Blood cell traits latent factor 3 (white cell)GCST905592458.89
420IDP dMRI TBSS OD Posterior limb of internal capsule RGCST900044208.88
421FCRL6/GZMA ratioGCST903148068.87
422HippSubfield lh volume Whole-hippocampusGCST900026898.87
423CRTAM/PDCD1 ratioGCST903142798.86
424Other systemic involvement of connective tissue (FG)FING000011168.84
425Atopic dermatitisGCST900185648.82
426Ceramide (d18:2/22:0) levelsGCST900240548.81
427Primary biliary cholangitis (PBC)FING000012118.81
428Prescriptions - albuterol | beta2-agonist,bronchodilator,asthmaUKBB000006588.80
429Prescriptions - beta2-agonist|bronchodilator|asthmaUKBB000006708.80
430SIGLEC1/SSC5D ratioGCST903158448.76
431GNLY/GZMA ratioGCST903149498.76
432Dementia due to Parkinson's disease (more control exclusions)FING000003928.73
433Ulcerative colitis (strict definition, require KELA, min 2 HDR)FING000013888.72
434Primary sclerosing cholangitisGCST0040308.68
435CataractsGCST900185948.67
436ENO2/PLXNA4 ratioGCST903146658.67
437SNRPB2 levelsGCST904706978.65
438Octadecenedioylcarnitine (C18:1-DC) levelsGCST901999708.64
439Neoplasm of uncertain behavior of skin (PheCode 173)GCST904755858.57
440Strenuous sports or other exercisesGCST0061008.55
441KLF4 levelsGCST904696948.54
442Asthma-related pneumoniaFING000001198.52
443CD27/TNFRSF9 ratioGCST903137788.50
444ZNF830 levelsGCST904711028.48
445CCL8 levelsGCST904223468.48
446BCL2 levelsGCST904684338.48
447Thoracic or lumbosacral neuritis or radiculitis, unspecified (PheCode 763)GCST904762688.47
448Acute pancreatitisFING000000278.46
449ConjunctivitisFING000003468.45
450Biological Sibling: AsthmaGCST904763728.45
451CD101 levelsGCST904685968.42
452Attendance/disability/mobility allowance - None of the above | Other sociodemographic factorsUKBB000000598.41
453Neurofibromatosis, type 2FING000008678.41
454EDAR/ERBIN ratioGCST903145758.40
455CCL17/PDGFB ratioGCST903136888.36
456DTI TBSS L2 Superior longitudinal fasciculus LGCST903845178.35
457Takes medication for Skin condition (ex. Eczema, Psoriasis)?GCST904752758.34
458FCRL5/ICAM3 ratioGCST903148028.31
459N-acetyl-2-aminoadipate levelsGCST902002688.30
460CXCL16 levelsGCST902405248.26
461Types of physical activity in last 4 weeks - None of the above | Physical activityUKBB000008728.24
462Margaroylcarnitine (C17) levelsGCST901999298.22
463Mean corpuscular haemoglobin concentration | Blood countUKBB000004488.21
464IL2RA/NCR1 ratioGCST903151618.19
465EDAR/TACC3 ratioGCST903145898.19
466MED18/TBL1X ratioGCST903154158.18
467CRTAP levelsGCST904688728.17
468DCTN1/TRIAP1 ratioGCST903144348.16
469Frequency of stair climbing in last 4 weeks | Physical activityUKBB000002668.15
470RPE levelsGCST904704958.11
471SUMF1 levelsGCST904707838.10
472Psoriatic arthropathiesFING000012258.10
473GZMA/LTA ratioGCST903150128.09
474TNFRSF9 levelsGCST904709168.08
475COPD/asthma/ILD related infectionsFING000003538.07
476DNMBP/WWP2 ratioGCST903145228.07
477BCR/FOXO1 ratioGCST903134908.06
478IL10 levelsGCST904695468.04
479DTI TBSS L3 Sagittal stratum LGCST903845558.03
480CALCOCO1/TJAP1 ratioGCST903136118.02
481Cervical cancerGCST900118168.01
482PEAR1/PECAM1 ratioGCST903156418.01
483Medication use (immunosuppressants)GCST900187718.00
484SnoringGCST0097627.99
485Dried fruit likingGCST900947567.99
486Papillary adenocarcinoma of thyroid gland, excluding all cancers (controls excluding all cancers)FING000011437.99
487IDO1 levelsGCST904695067.97
488Acute upper respiratory infections of multiple and unspecified sitesFING000000357.96
489Overweight, obesity and other hyperalimentation | endocrine/metabolicUKBB000006227.95
490Omega-3 fatty acids to total fatty acids percentageGCST905024607.93
491PTPRC levelsGCST904703807.92
492Principal component-derived dietary pattern 42GCST901330477.90
493Crohn's diseaseGCST904467937.86
494Long-standing illness, disability or infirmity | General healthUKBB000004097.86
495SNAP23/TBL1X ratioGCST903158567.85
496IL18 levelsGCST904284117.83
497CD6/EZR ratioGCST903138907.81
498Interpolated Age of participant when non-cancer illness first diagnosed | Medical conditionsUKBB000003697.79
499CD27/NECTIN4 ratioGCST903137757.76
500CEACAM8/PGLYRP1 ratioGCST903140037.75
501CD27/TNFRSF13B ratioGCST903137777.75
502DTI autoptx MD cgc l tractGCST903852247.73
503SMNDC1 levelsGCST904706817.72
504Allergic rhinitisFING000000717.70
505Peripheral or central vertigo (PheCode 386.2)GCST904759077.70
506Mean corpuscular volume (UKB data field 30040)GCST904680867.70
507Carboplatin drug response (IC50)GCST900117837.67
508T1 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 78)GCST903206417.67
509GZMA/TNFRSF4 ratioGCST903150137.67
510GZMA/TNFRSF8 ratioGCST903150147.65
511Solitary pulmonary nodule (PheCode 514.2)GCST904760447.63
512RAP1A levelsGCST904704257.63
513CEP43/MPHOSPH8 ratioGCST903140197.62
514CDC27 levelsGCST904686647.62
515Lymphangioleiomyomatosis (sporadic)GCST0083117.61
516TNF/TNFRSF1B ratioGCST903159427.61
517THBS2 levelsGCST904708547.60
518CD69/EDAR ratioGCST903138757.60
519PDCD1/TNFRSF4 ratioGCST903156097.60
520APBB1IP/POLR2F ratioGCST903133007.58
521Uterine fibroidsGCST904619587.58
522Mean corpuscular volume | Blood countUKBB000004497.55
523TNFRSF13B/TNFSF13B ratioGCST903159337.54
524Dizziness and giddiness (Light-headedness and vertigo) (PheCode 386.9)GCST904759087.53
525Prescriptions - antispasmodicUKBB000006667.52
526Crohn's diseaseGCST0041327.50
527Dried fruit consumptionGCST901329807.49
528FCRL5/TNFRSF13B ratioGCST903148057.49
529Other arthritis (FG)FING000009647.48
530Rhodanobacter abundance in stoolGCST900325367.48
531CXCL5/PLXNA4 ratioGCST903143517.48
532LTA4H levelsGCST904698127.44
533X-11550 levelsGCST902436487.44
534Principal component-derived dietary pattern 9GCST901330147.44
535PAXX levelsGCST904701617.43
536Sporadic miscarriageGCST0118887.43
537TP53BP1 levelsGCST904709367.43
538PSAPL1 levelsGCST902423547.42
539Mouth/teeth dental problems - Bleeding gums | MouthUKBB000004857.41
540Nonspecific chest pain | circulatory systemUKBB000005277.40
541Plasma ascorbic acid 2-sulfate levels in chronic kidney diseaseGCST902648327.37
542CD48 levelsGCST904686357.36
543Basophil countGCST900022937.36
544Mean spheric corpuscular volumeGCST900023977.34
545Allergic conjunctivitisFING000000677.34
546Bread type: Wholemeal or wholegrain (UKB data field 1448_3)GCST901329667.29
547KDM3A levelsGCST904696717.29
548Asthma with exacerbation (PheCode 495.2)GCST904760257.28
549EBAG9/FKBP5 ratioGCST903145647.26
550Treatment speciality of consultant (recoded) - Trauma & orthopaedics | Summary AdministrationUKBB000008377.25
551LPCAT2/SERPINB8 ratioGCST903153287.25
552Mean reticulocyte volume (UKB data field 30260)GCST904680887.19
553Tooth agenesis EXCLUDE clefts and syndromesFING000013687.19
554Never eat wheat vs no wheat restrictions (UKB data field 6144)GCST901329327.18
555ARG1 levelsGCST904683507.17
556Malignant neoplasm, excluding all cancers (controls excluding all cancers)FING000007807.14
557Mean corpuscular volumeGCST900023927.14
558TRAF2/WWP2 ratioGCST903159437.11
559DTI autoptx MD str r tractGCST903852447.10
560GZMA levelsGCST904694237.10
561ITGB1BP2/TIA1 ratioGCST903152227.08
562Ulcerative enterocolitisFING000013917.08
563Omega-3 fatty acids to Omega-6 fatty acids ratioGCST905023967.08
564Mean reticulocyte volumeGCST900023967.06
565Poultry consumptionGCST901329967.06
566PLXNB3/SNAP23 ratioGCST903156937.06
567FUT8/RSPO1 ratioGCST903148917.05
568Ankylosing spondylitis, strict definitionFING000000907.04
569Ulcerative rectosigmoiditisFING000013947.04
570VSTM2B levelsGCST904710567.03
571Rheumatoid arthritis and other inflammatory polyarthropathies | musculoskeletalUKBB000007587.02
572CXCL11/DKK1 ratioGCST903143347.01
573Cerebrospinal fluid methylmalonate (MMA) levelsGCST903182437.00
574FOXO1/USP8 ratioGCST903148796.99
575ITGB7 levelsGCST904696476.98
576CD48/SLAMF7 ratioGCST903138426.97
577Non-albumin protein levelsUKBB000005036.97
578IDP T1 SIENAX grey normalised volumeGCST900024306.96
579Other disorders of glucose regulation and pancreatic internal secretionFING000010286.94
580EBAG9/TGFB1 ratioGCST903145706.94
581TNFRSF11A levelsGCST902776446.94
582FOXO1/NFATC1 ratioGCST903148736.93
583GBP4 levelsGCST904693136.92
584SLAMF8 levelsGCST904706526.90
585IDP dMRI ProbtrackX L1 ifo rGCST900042596.90
586EDAR/SNAP23 ratioGCST903145876.88
587LHPP levelsGCST904697686.87
588DTI autoptx L3 ifo l tractGCST903852056.85
589TSC1 levelsGCST904709726.84
590CALCOCO1/IRAG2 ratioGCST903136046.82
591Ever SmokerFING000005226.81
592N-acetylmethionine levelsGCST902002896.80
593Nasal polypsGCST904681436.78
594Other circulatory problemGCST904752176.78
595MAVS/MED18 ratioGCST903153896.77
596Urine N-acetylglutamate levels in chronic kidney diseaseGCST902655696.76
597T1 FreeSurfer BA lh BA2 exvivo volumeGCST903855346.74
598T1 CAT volume L VIIIaGCST903841276.71
599Disorders of plasma protein metabolism (PheCode 270.3)GCST904757096.71
600Principal component-derived dietary pattern 28GCST901330336.69
601Diseases of white blood cells (PheCode 288)GCST904758126.69
602LAT/LYN ratioGCST903152836.68
603LBR/POLR2F ratioGCST903152976.68
604Bread type - Wholemeal or wholegrain | DietUKBB000001076.68
605CCL17/CD69 ratioGCST903136846.67
606DTI TBSS MD Superior longitudinal fasciculus RGCST903846126.66
607Non-allergic asthma (mode) (more control exclusions)FING000008696.63
608IL32 levelsGCST904695916.61
609CD244 levelsGCST904686116.60
610TNFSF13B levelsGCST904709206.60
611Atrophic disorders of skinFING000001296.60
612Mood swings | Mental healthUKBB000004826.59
613Mean corpuscular volumeGCST0046026.56
614ENO2/HCLS1 ratioGCST903146606.56
615MINPP1 levelsGCST902419786.56
616Thyrotoxicosis with or without goiter (PheCode 242)GCST904756436.53
617Right-hemisphere visual network to right-hemisphere dorsal attention network white-matter structural connectivityGCST903027766.53
618DTI TBSS MD Posterior limb of internal capsule LGCST903845916.53
619CD27/CD79B ratioGCST903137706.52
620Never eat wheat vs no eggs, dairy, wheat or sugar restrictions (UKB data field 6144)GCST901329316.50
621SELPLG levelsGCST904705686.49
622Obesity | endocrine/metabolicUKBB000005446.49
623Principal component-derived dietary pattern 21GCST901330266.47
624FCRL1/TCL1A ratioGCST903147956.46
625Obesity | Obesity and other hyperalimentationUKBB000005456.44
626IDP T1 SIENAX grey unnormalised volumeGCST900024316.43
627KYNU/SCLY ratioGCST903152656.42
628APP/HBEGF ratioGCST903133246.41
629APRT levelsGCST904683456.41
630MICB_MICA/TEK ratioGCST903154466.41
631IL15/KLRD1 ratioGCST903151496.39
632Low hand grip strength (60 years and older) (FNIH)GCST900075296.39
633Lung cancerGCST900186556.38
634CASP10 levelsGCST904685426.37
635Moderate-to-vigorous intensity physical activity during leisure timeGCST901043416.37
636Prospective memory result | Prospective memoryUKBB000007136.36
637Educational attainmentGCST0025986.35
638SnoringGCST0097606.35
639MAP3K5/MAVS ratioGCST903153796.34
640ERBIN/LYN ratioGCST903146946.34
641N2-acetyl,N6,N6-dimethyllysine levelsGCST902006976.33
642DTI autoptx FA slf l tractGCST903851336.31
643FCRL6/KLRD1 ratioGCST903148076.29
644Squamous cell carcinoma (PheCode 172.22)GCST904755836.27
645NFATC3 levelsGCST904700346.27
646MAN2B2 levelsGCST904698446.26
647HEXIM1/TRIAP1 ratioGCST903150546.25
648SRC/TBL1X ratioGCST903158846.23
649Crohns diseaseGCST904681216.23
650Pain in throat and chest | Symptoms and signs involving the circulatory and respiratory systemsUKBB000006256.23
651Ratio of bis-allylic bonds to double bonds in lipidsGCST901327446.22
652Diseases of the digestive systemFING000004296.21
653Idiopathic pulmonary fibrosisFING000006596.19
654Mean corpuscular hemoglobinGCST900023906.18
655DAG1/F2R ratioGCST903143746.18
656Lung adenocarcinomaGCST0047446.18
657Citrulline levelsGCST902004036.17
658Frailty (Factor 4 - Metabolic Problems)GCST906240506.16
659Belief that own life is meaningful | Happiness and subjective well-beingUKBB000000906.15
660GALNT10/SEMA7A ratioGCST903149156.14
661TNFRSF13B levelsGCST904709056.12
662CDH17/SPINT1 ratioGCST903139446.11
663Basal cell carcinoma, including avohilmo, excluding all cancers (controls excluding all cancers)FING000001436.11
664DBNL/EDAR ratioGCST903144166.11
665ROR1/THBD ratioGCST903157866.10
666AXIN1/ITGB1BP2 ratioGCST903134126.09
667Mean corpuscular haemoglobin | Blood countUKBB000004476.09
668Avocado likingGCST900946946.06
669Other and/or unspecified nontoxic goitreFING000009586.06
670Ulcerative colitisGCST900187136.05
671UCMA levelsGCST902432856.04
672Hair colour (natural, before greying): Red (UKB data field 1747_2)GCST900418376.03
673Other and unspecified psoriasisFING000009506.02
674Mean corpuscular haemoglobin (UKB data field 30050)GCST904680846.02
675INPP5J levelsGCST904696186.01
676Tobacco use disorder | mental disordersUKBB000008246.01
677Basal cell carcinoma, excluding all cancers (controls excluding all cancers)FING000001426.00
678PFKM levelsGCST906188026.00
679Other acute lower respiratory infectionsFING000009215.99
680Osteoarthrosis NOS (PheCode 740.9)GCST904762565.98
681Other demyelinating diseases of the central nervous systemFING000009955.97
682AHSP/BLVRB ratioGCST903132145.97
683Chronic dermatitis due to solar radiation (PheCode 938.2)GCST904762885.96
684PM: initial answer - Orange circle| Prospective memoryUKBB000006525.95
685Chronic nephritic syndromeFING000002955.94
686Plasma taurocholenate sulfate* levels in chronic kidney diseaseGCST902660405.94
687TCL1A/TNFRSF13C ratioGCST903159125.92
688HSPA1A levelsGCST904694875.92
689Bifidobacterium catenulatum abundance in stoolGCST900322245.91
690Malignant neoplasm of thyroid gland, excluding all cancers (controls excluding all cancers)FING000007775.90
691DTI TBSS MD Superior longitudinal fasciculus LGCST903846135.89
692HAVCR2 levelsGCST904215155.89
693DTI autoptx L1 cst l tractGCST903851475.86
694Polymyalgia rheumaticaFING000011885.85
695General happiness | Happiness and subjective well-beingUKBB000002805.84
696BCR/ITGB1BP2 ratioGCST903134945.84
697DTI TBSS L3 Superior corona radiata LGCST903845495.83
698PPP1R14D levelsGCST904703035.83
699UGDH levelsGCST904710065.83
700Mean corpuscular haemoglobin concentration (UKB data field 30060)GCST904680855.82
701IGSF8/NECTIN2 ratioGCST903151405.82
702TNFRSF4 levelsGCST904709135.82
703aparc-a2009s rh thickness G-oc-temp-med-LingualGCST900036985.81
704Low hand grip strength (60 years and older) (EWGSOP)GCST900075275.81
705Ulcerative colitisGCST904753225.81
706NBN levelsGCST904700025.81
707Spondylopathies (FG)FING000013265.80
708mean corpuscular hemoglobin (MCH, minimum, inv-norm transformed)GCST904754485.79
709Mean corpuscular hemoglobinGCST0046305.79
710NELL1 levelsGCST902424815.78
711HBEGF/PDGFA ratioGCST903150335.78
712Diseases of middle ear and mastoidFING000004275.78
713Bipolar disorderGCST0037245.78
714ADAM12 levelsGCST904682165.77
715CD86 levelsGCST904686545.77
716Basophil countGCST900187265.74
717Crohn's diseaseGCST904753185.74
718LCN2/PGLYRP1 ratioGCST903153065.74
719DNA methylation-estimated granulocyte proportionsGCST900142875.73
720Vertiginous syndromes and other disorders of vestibular system (PheCode 386)GCST904759055.72
721Alcohol-induced chronic pancreatitisFING000000555.70
722Smoking status (standard GWA)GCST902673025.70
723ITGB1BP2/USP8 ratioGCST903152235.70
724Actinic keratosis (PheCode 702.1)GCST904762045.69
725DCTN6/TDRKH ratioGCST903144365.69
726PCBD1 levelsGCST904701665.69
727DTI TBSS MD Superior corona radiata RGCST903845965.68
728Lumbar disc prolapseFING000007355.68
729EDAR/IPCEF1 ratioGCST903145785.68
730PROK1 levelsGCST904703365.68
731Aniseed likingGCST900946895.66
732mean corpuscular hemoglobin (MCH, mean, inv-norm transformed)GCST904754445.65
733Left-hemisphere salience/ventral attention network to amygdala white-matter structural connectivityGCST903027245.64
734Ankylosing spondylitisFING000000895.63
735NME3 levelsGCST904700555.61
736LRRC37A2 levelsGCST904698025.61
737PollinosisGCST900186835.61
738FCRL5 levelsGCST904692085.61
739DTI TBSS L1 Anterior corona radiata RGCST903844505.59
740IL16 levelsGCST904695575.58
741Immature reticulocyte fraction | Blood countUKBB000003555.58
742F5 levelsGCST904464665.58
743EFNA4/TNFRSF9 ratioGCST903146065.57
744Carcinoma in situ of breast, intraductal (controls excluding all cancers)FING000002405.56
745DNA methylation PhenoAge accelerationGCST900142925.56
746Degenerative skin conditions and other dermatoses (PheCode 702)GCST904762025.52
747Other intervertebral disc disordersFING000010635.52
748UNC5D levelsGCST904710105.50
749CWC15 levelsGCST904689205.50
750Number of days/week walked 10+ minutes | Physical activityUKBB000005355.49
751IL5RA levelsGCST904696005.49
752DTI autoptx MD fma tractGCST903852305.48
753Principal component-derived dietary pattern 26GCST901330315.48
754Number of attempts | Prospective memoryUKBB000005315.48
755Left-hemisphere somatomotor network to left-hemisphere control network white-matter structural connectivityGCST903026735.47
756LBR/LGALS8 ratioGCST903152945.47
757CHMP1A/RHOC ratioGCST903140535.47
758CRACR2A/IRAG2 ratioGCST903142275.47
759Acute renal failureFING000000305.45
760Other contact dermatitisFING000009905.44
761HippSubfield lh volume Whole-hippocampal-bodyGCST900026875.44
762BTN3A2 levelsGCST904684815.43
763CD22/TCL1A ratioGCST903137605.43
764Neutrophill percentage (UKB data field 30200)GCST904680935.42
765HippSubfield lh volume CA4-bodyGCST900026835.42
766HMBS/PKLR ratioGCST903150635.40
767ARHGAP25/RNF41 ratioGCST903133455.40
7685alpha-pregnan-3beta,20alpha-diol monosulfate (2) levelsGCST901998545.39
769Neutrophill percentage | Blood countUKBB000004985.38
770Peripheral enthesopathies and allied syndromes | musculoskeletalUKBB000006405.38
771IDP dMRI TBSS ISOVF Genu of corpus callosumGCST900044795.38
772Cerebral aneurysm, nonrupturedFING000002635.36
773SLITRK2 levelsGCST904706705.35
774Leisure/social activities - None of the above | Social supportUKBB000003995.33
775neutrophil (fraction, mean, inv-norm transformed)GCST904755385.32
776Open biteFING000009035.32
777SLAMF1 levelsGCST904706495.32
778DTI autoptx MD slf r tractGCST903852425.32
779Active to sedentary transition probabilityGCST900614295.32
780BACH1/SNAP23 ratioGCST903134465.29
781Plasma N-acetyltaurine levels in chronic kidney diseaseGCST902656005.29
782Omega-3 fatty acids to total fatty acids percentageGCST905024485.28
783Current SmokerFING000003715.27
784LAT/PLXNA4 ratioGCST903152865.26
785Prescriptions - paracetamol | antipyreticUKBB000006965.26
786Prescriptions - antipyreticUKBB000006655.26
787Benign leiomyoma with endometriosis (controls excluding all cancers)FING000001455.26
788Other malignant neoplasms of skin (=non-melanoma skin cancer), excluding all cancers (controls excluding all cancers)FING000010675.25
789CXCL5/MESD ratioGCST903143505.24
790DTI autoptx L1 slf r tractGCST903851615.24
791APEX1 levelsGCST904683295.24
792KLK8/WFDC12 ratioGCST903152595.23
793ENO3 levelsGCST904691115.22
794CALCOCO1/PDLIM7 ratioGCST903136075.21
795Suppurative and unspecified otitis mediaFING000013465.21
796Fruit intake (weighted GWA)GCST902672835.20
797All pneumoniaeFING000000655.19
798PM: initial answer - Blue square | Prospective memoryUKBB000006515.19
799HBEGF/WWP2 ratioGCST903150385.18
800F2R/SNX9 ratioGCST903147365.16
801Melanomas of skin (PheCode 172.11)GCST904755785.15
802Time spent watching television (TV) | Physical activityUKBB000008215.15
803AHCY/HSPA1A ratioGCST903132115.14
804NHLRC3 levelsGCST904700465.13
805Telomere length (principal component 1)GCST904351445.13
806LY96 levelsGCST904698235.12
807Neutrophil percentage of white cellsGCST900023995.11
808Colitis, primary sclerosing, strict definitionFING000003135.11
809AsthmaGCST900860475.10
810N-acetyl-1-methylhistidine levelsGCST902006905.09
811How are people in household related to participant - Husband, wife or partner | HouseholdUKBB000003305.08
812Mental and behavioural disorders due to use of tobacco | Mental and behavioural disorders due to psychoactive substance useUKBB000004605.08
813Neoplasm of uncertain behavior (PheCode 199)GCST904756065.07
814T1 FreeSurfer a2009s lh S postcentral areaGCST903847345.06
815AHSP/HMBS ratioGCST903132175.06
816Bread type - White | DietUKBB000001065.06
817Right-hemisphere control network to amygdala white-matter structural connectivityGCST903028415.06
818Other and unspecified tonsillitisFING000009545.05
819ACYP1 levelsGCST904682145.05
820FUT8/PDGFA ratioGCST903148905.05
821Excessive vomiting in pregnancyFING000005235.05
822Trouble falling asleep when you first go to bedGCST904763855.04
823Other cancerGCST904751815.04
824GBP1 levelsGCST904693115.04
825Crohn's disease of large intestineFING000003685.04
826T1 FreeSurfer aseg Right-PallidumGCST903841645.03
827Cancer of bronchus; lung (PheCode 165.1)GCST904755735.02
828CEP85 levelsGCST904687165.02
829STK24/TDRKH ratioGCST903158935.02
830HBEGF/PLXNA4 ratioGCST903150365.00
831Lung cancerGCST0047485.00
832Red blood cell (erythrocyte) distribution width | Blood countUKBB000007484.99
833CCN2/HBEGF ratioGCST903137134.98
834NCAN levelsGCST906185594.97
835IPCEF1/SERPINE1 ratioGCST903151844.95
836DTI autoptx FA ifo l tractGCST903851244.95
837Dried fruit intake | DietUKBB000001934.94
838CDH17/PECAM1 ratioGCST903139424.94
839ITGB1BP2/WASF1 ratioGCST903152244.94
840Symptoms involving digestive system (PheCode 561)GCST904760694.92
841Back pain (PheCode 760)GCST904762664.91
842SUGT1/TBL1X ratioGCST903158974.91
843CDKN2D/FOXO1 ratioGCST903139854.91
844AXIN1/MAVS ratioGCST903134144.90
845F11R/SORT1 ratioGCST903147264.88
846Use of hypnotics and sedativesFING000014114.88
847Diseases of esophagus (PheCode 530)GCST904760454.86
848MAD1L1/POLR2F ratioGCST903153544.85
849Prostate cancerGCST900186854.84
850NELL2/SEZ6L ratioGCST903155364.84
851Psoriasis (vulgaris), strict definitionFING000012234.84
852Physical activityGCST900933224.84
853Dermatitis due to ingested foodFING000004034.83
854DNAJB14 levelsGCST904272354.82
855Non-cancer illness year/age first occurred | Medical conditionsUKBB000005234.82
856Actinic keratosisFING000000134.82
857CEP43/USP8 ratioGCST903140224.81
858MAP2K1 levelsGCST904698514.81
859Number in household | HouseholdUKBB000005304.81
860Bread type: White (UKB data field 1448_1)GCST901329644.80
861Percentage of fucosylated structures (with bisecting GlcNAc) in total neutral plasma glycans (GP80)GCST906685244.80
862APBB1IP levelsGCST904683274.79
863FASLG levelsGCST904691914.78
864CD69/NFATC1 ratioGCST903138794.78
865EDAR/F2R ratioGCST903145774.77
866RHOC/TBCB ratioGCST903157744.76
867Juvenile rheumatoid arthirtisFING000007064.76
868COX5B/GFER ratioGCST903142004.74
869VegetarianismGCST904288384.73
870T1 FreeSurfer DK rh supramarginal volumeGCST903857874.71
871S100A11/SERPINB8 ratioGCST903157994.70
872Takes medication for asthma?GCST904752604.70
873Raynauds phenomenon diseaseGCST902717134.69
874Uterine fibroidsGCST904681544.69
875CLEC1B/HBEGF ratioGCST903140924.69
876LCN2/S100A12 ratioGCST903153094.69
877CLEC4D/CLEC6A ratioGCST903141094.68
878PPM1B levelsGCST904702964.67
879Other dorsopathies, not elsewhere classifiedFING000010414.66
880Diseases of vocal cords and larynx+other diseases of upper respiratory tract, no elsewhere classifiedFING000004324.66
881BleedingFING000002194.65
882Red blood cell countGCST900187514.65
883ALB/Globulin ratioUKBB000000204.65
884TXNDC15 levelsGCST904709904.65
885T1 CAT volume R RightPutamenGCST903841014.65
886RIDA levelsGCST904704694.63
887COL1A1 levelsGCST902407444.63
888Multiple myeloma, Monoclonal gammopathy of undetermined significance (MGUS), excluding all cancers (controls excluding all cancers)FING000008464.62
889ESAM/FUT8 ratioGCST903147114.62
890Left-hemisphere dorsal attention network to putamen white-matter structural connectivityGCST903027034.61
891DTI TBSS MD External capsule LGCST903846054.60
892QPCT/RNASET2 ratioGCST903157584.60
893mean platelet volume (MPV, maximum, inv-norm transformed)GCST904755174.60
894JCHAIN levelsGCST904696614.59
895Basophil countGCST900259974.59
896neutrophil (fraction, maximum, inv-norm transformed)GCST904755354.59
897CDH17/PTPRM ratioGCST903139434.59
898MICB or MICA levelsGCST904699054.58
899DKK1/IPCEF1 ratioGCST903144714.57
900Cooked vegetable intake | DietUKBB000001474.57
901GFRA2 levelsGCST904693294.57
902Infections of the skin and subcutaneous tissueFING000006704.55
903Right-hemisphere control network to right-hemisphere control network white-matter structural connectivityGCST903028344.55
904Other obstetric traumaFING000010824.54
905DAB2/FKBP1B ratioGCST903143624.54
906EDAR/EGF ratioGCST903145734.54
907MSRA/PRDX5 ratioGCST903154974.54
908AXL/IL18BP ratioGCST903134204.54
909PLAT levelsGCST904702504.53
910aparc-DKTatlas rh thickness lingualGCST900035824.53
911DTI TBSS L3 Genu of corpus callosumGCST903845264.52
912BAG6/BMP6 ratioGCST903134504.52
913Takes medication for Chronic lung diseases including COPD, Emphysema and Bronchitis?GCST904752734.52
914ICD10 N87: Dysplasia of cervix uteriGCST904542184.52
915Gastroesophageal reflux diseaseGCST900005144.51
916Redundant prepuce, phimosis and paraphimosisFING000012464.50
917Cereal intake | DietUKBB000001214.49
918Bread type: White vs wholemeal/wholegrain and brown (UKB data field 1448)GCST901329674.49
919Overweight, obesity and other hyperalimentation (PheCode 278)GCST904757594.49
920Acquired hypothyroidism (PheCode 244.2)GCST904756504.48
921Principal component-derived dietary pattern 29GCST901330344.48
922IDP dMRI TBSS ISOVF Anterior corona radiata LGCST900045004.48
923Type 1 diabetesGCST900187054.48
924Physical activity (Total log acceleration 12am-2am)GCST900614094.46
925TRAF3 levelsGCST904709574.46
926FCER1A levelsGCST904691984.46
927CA3/HMBS ratioGCST903135844.44
928Mineral and other dietary supplements - Glucosamine | MedicationUKBB000004734.44
929IL19 levelsGCST904695684.43
930SPINK2 levelsGCST904707224.43
931ICAM4 levelsGCST904695014.41
932PSIP1 levelsGCST904703544.41
933IPCEF1 levelsGCST904696244.41
934Red blood cell erythrocyte distribution width (UKB data field 30070)GCST904680994.41
935CAPS levelsGCST904685394.40
936DTI autoptx MD slf l tractGCST903852414.40
937Usual side of head for mobile phone use - Left | Electronic device useUKBB000008894.40
938AHNAK levelsGCST904682614.40
939PLXNA4/VASH1 ratioGCST903156914.40
940AMOTL2 levelsGCST904682944.40
941ERBB4/F3 ratioGCST903146904.39
942NADK/S100A11 ratioGCST903155134.38
943ThalamNuclei lh volume MDlGCST900027244.36
944CALCOCO1/TBC1D5 ratioGCST903136104.35
945CCR2 on CD14+ CD16- monocyteGCST900020044.35
946Symbol digit substitution test performance (baseline)GCST905658414.32
947ADA levelsGCST904682314.32
948Internal derangement of knee (PheCode 835)GCST904762824.32
949X-21286 levelsGCST902005624.32
950Omega-3 fatty acids to total fatty acids percentageGCST905020874.32
951IDP T1 SIENAX brain-normalised volumeGCST900024344.32
952Types of physical activity in last 4 weeks - Other exercises (eg: swimming, cycling, keep fit, bowling) | Physical activityUKBB000008734.31
953Other Crohn's diseaseFING000009924.31
954IDP dMRI TBSS L1 Posterior limb of internal capsule LGCST900040944.30
955LGALS3BP levelsGCST904697604.30
956Left-hemisphere dorsal attention network to right-hemisphere salience/ventral attention network white-matter structural connectivityGCST903026974.30
957Percentage of fucosylated structures (with bisecting GlcNAc) in total neutral plasma glycans (GP80)GCST906687584.29
958Thyroid cancer (PheCode 193)GCST904756004.28
959FAM13A levelsGCST904691814.28
960Operation code - spine or back surgery | OperationsUKBB000005654.27
961Malignant neoplasm of lip, excluding all cancers (controls excluding all cancers)FING000007644.27
962GIMAP7 levelsGCST904693454.27
963Percentage of fucosylation of monogalactosylated structures in total neutral plasma glycans (GP74)GCST906685184.27
964EDAR/ITGB1BP2 ratioGCST903145804.27
965Parkinson's diseaseFING000011504.25
966Red cell distribution widthGCST900024044.25
967Accelerometer-based physical activity measurement (average acceleration)GCST0060994.25
968DTI autoptx L3 slf r tractGCST903852154.25
969FUT8/VEGFC ratioGCST903148964.24
970SNX15 levelsGCST904706994.24
971CD5L levelsGCST904686404.23
972HippSubfield lh volume GC-ML-DG-bodyGCST900026814.23
973Skin cancer | neoplasmsUKBB000007724.23
974ICAM5 levelsGCST904695024.22
9752,3-dihydroxy-5-methylthio-4-pentenoate (dmtpa) levelsGCST902002334.21
9763-methyl-2-oxobutyrate levelsGCST901996774.21
977DBNL/HSPA1A ratioGCST903144184.20
978SMPD3 levelsGCST904706854.20
979ITGB1BP2/PTPN6 ratioGCST903152184.19
980Hypoplasia of dental enamel, including avohilmoFING000006524.19
981GRAP2/MAP4K5 ratioGCST903149824.19
982PBLD levelsGCST904701634.19
983Estradiol levelsGCST900121054.19
984Phosphatidylcholine acyl-alkyl C36:5 levelsGCST902400734.18
985Left-hemisphere limbic network to right-hemisphere dorsal attention network white-matter structural connectivityGCST903027314.18
986aparc-Desikan rh thickness lingualGCST900034914.17
987Disorders of eyelid, lacrimal system and orbitFING000004394.17
988BIN2/FYB1 ratioGCST903135054.17
989Cancer of bladder (PheCode 189.2)GCST904755984.16
990Principal component-derived dietary pattern 16GCST901330214.15
991Cancer within the respiratory system (PheCode 165)GCST904755714.15
992FUT3 or FUT5 levelsGCST904692804.14
993Left-hemisphere visual network to left-hemisphere visual network white-matter structural connectivityGCST903026484.14
994CALCOCO1/VPS53 ratioGCST903136124.14
995INSL5 levelsGCST904696224.13
996ATP5IF1/FXN ratioGCST903133864.13
997Cervical disc disordersFING000002654.12
998BACH1/CD2AP ratioGCST903134354.12
999Left-hemisphere default mode network to right-hemisphere dorsal attention network white-matter structural connectivityGCST903027624.12
1000Educational attainment (confirmatory factor analysis Factor 10)GCST903093444.12